Publications
- Newest First
- Most Cited
- Most Discussed
Showing 1 - 100 results of 2,597 publications
2024
- Psychosocial burden of autoimmune blistering diseases: A comprehensive survey studyWhite M, Hoffman V, Yale M, Strong R, Tomayko M. Psychosocial burden of autoimmune blistering diseases: A comprehensive survey study. Journal Of The European Academy Of Dermatology And Venereology 2024 PMID: 38837452, DOI: 10.1111/jdv.20156.
- Granuloma Annulare Exhibits Mixed Immune and Macrophage Polarization Profiles with Spatial TranscriptomicsMohanty C, Singh C, Daccache J, Damsky W, Kendziorski C, Yan D, Prasad A, Zhang D, Keenan T, Drolet B, Ahmad N, Shields B. Granuloma Annulare Exhibits Mixed Immune and Macrophage Polarization Profiles with Spatial Transcriptomics. Journal Of Investigative Dermatology 2024 PMID: 38844128, DOI: 10.1016/j.jid.2024.04.024.
- A Unique Presentation of Nodular Masses in Infancy.Velagala S, Heiden E, Lisse S, Wu H, Prior D, Chen G, Christison-Lagay E, Provini L, Antaya R, Spencer-Manzon M, Johnston L. A Unique Presentation of Nodular Masses in Infancy. NeoReviews 2024, 25: e370-e374. PMID: 38821908, DOI: 10.1542/neo.25-6-e370.
- A plasma-based proteomic platform for predicting clinical benefit from immune checkpoint inhibitors in multiple cancers.Sela I, Lahav C, Lowenthal G, Harel M, Elon Y, Yellin B, Dicker A, Halaban R, Marte J, Sznol M, Gulley J. A plasma-based proteomic platform for predicting clinical benefit from immune checkpoint inhibitors in multiple cancers. Journal Of Clinical Oncology 2024, 42: 2568-2568. DOI: 10.1200/jco.2024.42.16_suppl.2568.
- Association between psoriasis and obsessive-compulsive disorder: a case-control study in the All of Us research programCraver A, Chen G, Fan R, Levey D, Cohen J. Association between psoriasis and obsessive-compulsive disorder: a case-control study in the All of Us research program. Archives Of Dermatological Research 2024, 316: 280. PMID: 38796663, DOI: 10.1007/s00403-024-03112-y.
- Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramKing B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, Sinclair R, Mesinkovska N, Paul C, Gong Y, Anway S, Tran H, Wolk R, Zwillich S, Lejeune A. Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. American Journal Of Clinical Dermatology 2024, 1-1. PMID: 38789821, DOI: 10.1007/s40257-024-00864-1.
- Barriers to care and health-related quality of life among US adults with several common chronic inflammatory skin diseases: a cross-sectional analysis of the NIH All of Us Research ProgramNock M, Barbieri J, Cohen J. Barriers to care and health-related quality of life among US adults with several common chronic inflammatory skin diseases: a cross-sectional analysis of the NIH All of Us Research Program. Archives Of Dermatological Research 2024, 316: 201. PMID: 38775812, DOI: 10.1007/s00403-024-02954-w.
- Efficacy of laser hair removal in hidradenitis suppurativa: A systematic review and meta‐analysisShipman W, Williams M, Suozzi K, Eisenstein A, Dover J. Efficacy of laser hair removal in hidradenitis suppurativa: A systematic review and meta‐analysis. Lasers In Surgery And Medicine 2024, 56: 425-436. PMID: 38769894, DOI: 10.1002/lsm.23796.
- The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported CasesPach J, Valido K, Belzer A, Leventhal J. The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases. American Journal Of Clinical Dermatology 2024, 1-13. PMID: 38767827, DOI: 10.1007/s40257-024-00866-z.
- The development of hair follicles and nailLee S, Platt S, Lim C, Ito M, Myung P. The development of hair follicles and nail. Developmental Biology 2024, 513: 3-11. PMID: 38759942, DOI: 10.1016/j.ydbio.2024.05.010.
- Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 AnalysisKircik L, Stein Gold L, Gold M, Weiss J, Harper J, Del Rosso J, Bunick C, Bhatia N, Tanghetti E, Eichenfield L, Baldwin H, Draelos Z, Callender V, Han G, Gooderham M, Sadick N, Lupo M, Lain E, Werschler W. Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis. Dermatology And Therapy 2024, 14: 1211-1227. PMID: 38724841, PMCID: PMC11116301, DOI: 10.1007/s13555-024-01155-7.
- Topical ruxolitinib for facial blaschkitis in an adolescentZarowin D, Provini L, Antaya R. Topical ruxolitinib for facial blaschkitis in an adolescent. Pediatric Dermatology 2024 PMID: 38716713, DOI: 10.1111/pde.15640.
- Adenocarcinoma of anogenital mammary gland type arising from encapsulated papillary carcinoma: A rare vulvar tumor mimicking breast carcinomaTang H, Laskin W, Luan Y, McNiff J, Zhan H. Adenocarcinoma of anogenital mammary gland type arising from encapsulated papillary carcinoma: A rare vulvar tumor mimicking breast carcinoma. Journal Of Cutaneous Pathology 2024 PMID: 38711196, DOI: 10.1111/cup.14639.
- Intravenous immunoglobulin-induced eczematous dermatitis treated with dupilumabSingh K, Breidbart R, Jaiswal A, Damsky W, Choate K, Vesely M. Intravenous immunoglobulin-induced eczematous dermatitis treated with dupilumab. JAAD Case Reports 2024, 49: 102-105. DOI: 10.1016/j.jdcr.2024.05.002.
- Hyaluronic Acid Filler for Lip Augmentation in Patients with Systemic Sclerosis: A Prospective Cohort StudySwallow M, Elgash M, Kim R, Hinchcliff M, Suozzi K. Hyaluronic Acid Filler for Lip Augmentation in Patients with Systemic Sclerosis: A Prospective Cohort Study. JAAD Case Reports 2024 DOI: 10.1016/j.jdcr.2024.05.006.
- Topical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances.Del Rosso J, Bunick C, Kircik L, Bhatia N. Topical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances. Journal Of Drugs In Dermatology 2024, 23: 438-445. PMID: 38834223, DOI: 10.36849/jdd.8318.
- Oncogenic Kras induces spatiotemporally specific tissue deformation through converting pulsatile into sustained ERK activationXin T, Gallini S, Wei H, Gonzalez D, Matte-Martone C, Machida H, Fujiwara H, Pasolli H, Suozzi K, Gonzalez L, Regot S, Greco V. Oncogenic Kras induces spatiotemporally specific tissue deformation through converting pulsatile into sustained ERK activation. Nature Cell Biology 2024, 26: 859-867. PMID: 38689013, DOI: 10.1038/s41556-024-01413-y.
- Unveiling the secrets of vimentin filament architecture relevant to human diseaseLomakin I, Ho M, Bunick C. Unveiling the secrets of vimentin filament architecture relevant to human disease. Nature Structural & Molecular Biology 2024, 1-3. PMID: 38684931, DOI: 10.1038/s41594-024-01301-x.
- Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunityZhang T, Yu W, Cheng X, Yeung J, Ahumada V, Norris P, Pearson M, Yang X, van Deursen W, Halcovich C, Nassar A, Vesely M, Zhang Y, Zhang J, Ji L, Flies D, Liu L, Langermann S, LaRochelle W, Humphrey R, Zhao D, Zhang Q, Zhang J, Gu R, Schalper K, Sanmamed M, Chen L. Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity. Science Immunology 2024, 9: eadh2334. PMID: 38669316, DOI: 10.1126/sciimmunol.adh2334.
- Stigmatization and Mental Health Impact of Chronic Pediatric Skin DisordersPaller A, Rangel S, Chamlin S, Hajek A, Phan S, Hogeling M, Castelo-Soccio L, Lara-Corrales I, Arkin L, Lawley L, Funk T, Lopes F, Antaya R, Ramien M, Vivar K, Teng J, Coughlin C, Rehmus W, Gupta D, Bercovitch L, Stein S, Boull C, Tom W, Liang M, Hunt R, Luu M, Holland K, Schoch J, Cella D, Lai J, Griffith J. Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders. JAMA Dermatology 2024, 160 PMID: 38656377, PMCID: PMC11044010, DOI: 10.1001/jamadermatol.2024.0594.
- 08. Proteomic Profiling of Tumor Microenvironment In Desmoplastic Melanoma Using The Nanostring Geomx Digital Spatial ProfilerSu D, Galan A, Schoenfeld D, Ibrahim W, Cabrejo R, Baumann R, Rimm D, Khan S, Kluger H, Olino K, Clune J. 08. Proteomic Profiling of Tumor Microenvironment In Desmoplastic Melanoma Using The Nanostring Geomx Digital Spatial Profiler. Plastic & Reconstructive Surgery Global Open 2024, 12: 6-6. PMCID: PMC11041221, DOI: 10.1097/01.gox.0001015124.74133.52.
- Successful use of picosecond laser treatment for seborrheic keratosis in three Asian patientsSwallow M, Elgash M, Kim R, Suozzi K. Successful use of picosecond laser treatment for seborrheic keratosis in three Asian patients. JAAD Case Reports 2024, 48: 46-48. PMID: 38774669, PMCID: PMC11107074, DOI: 10.1016/j.jdcr.2024.04.006.
- Altered skin microbiome, inflammation, and JAK/STAT signaling in Southeast Asian ichthyosis patientsHo M, Nguyen H, Van Hoang M, Bui T, Vu B, Dinh T, Vo H, Blaydon D, Eldirany S, Bunick C, Bui C. Altered skin microbiome, inflammation, and JAK/STAT signaling in Southeast Asian ichthyosis patients. Human Genomics 2024, 18: 38. PMID: 38627868, PMCID: PMC11022333, DOI: 10.1186/s40246-024-00603-x.
- Crystal Structure of Bimekizumab Fab Fragment in Complex with IL-17F Provides Molecular Basis for Dual IL-17A and IL-17F InhibitionAdams R, Bunick C, Lawson A, Gomez B, Shaw S. Crystal Structure of Bimekizumab Fab Fragment in Complex with IL-17F Provides Molecular Basis for Dual IL-17A and IL-17F Inhibition. Journal Of Investigative Dermatology 2024 PMID: 38631666, DOI: 10.1016/j.jid.2024.03.037.
- Successful treatment of pityriasis rubra pilaris with brodalumab after nonresponse to IL-17A inhibition: A role for the innate cytokine IL-17CValido K, Murphy M, Leventhal J, Damsky W. Successful treatment of pityriasis rubra pilaris with brodalumab after nonresponse to IL-17A inhibition: A role for the innate cytokine IL-17C. JAAD Case Reports 2024, 48: 85-87. PMID: 38783931, PMCID: PMC11111584, DOI: 10.1016/j.jdcr.2024.04.010.
- Characterizing interstitial lung disease among patients with psoriasis: A cross-sectional analysis in the NIH All of Us Research ProgramShaw V, Damsky W, Homer R, Cohen J. Characterizing interstitial lung disease among patients with psoriasis: A cross-sectional analysis in the NIH All of Us Research Program. Clinical And Experimental Dermatology 2024, llae132. PMID: 38618708, DOI: 10.1093/ced/llae132.
- Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB SignalingVelasco R, Shao C, Cutler B, Strunck J, Kent G, Cassidy P, Choate K, Greiling T. Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling. JAMA Dermatology 2024, 160 PMID: 38598229, PMCID: PMC11007649, DOI: 10.1001/jamadermatol.2024.0257.
- Paradoxical PsoriasisAbdelghaffar M, Kottilil S, Murphy M, Cohen J, Damsky W. Paradoxical Psoriasis. Dermatologic Clinics 2024, 42: 471-480. PMID: 38796276, DOI: 10.1016/j.det.2024.02.011.
- Treatment of prolonged drug reaction with eosinophilia and systemic symptoms syndrome with dupilumab using a molecularly-guided approachValido K, Patel V, Murphy M, Junejo M, Patel D, Deutsch A, Turner N, Zaki T, King B, Damsky W, Nelson C. Treatment of prolonged drug reaction with eosinophilia and systemic symptoms syndrome with dupilumab using a molecularly-guided approach. JAAD Case Reports 2024, 48: 49-53. PMID: 38774671, PMCID: PMC11107093, DOI: 10.1016/j.jdcr.2024.03.020.
- Association of Lichen Planus with Asthma and Allergic Rhinitis in the All of Us Research Program: A Cross-Sectional StudyRichmond R, Murphy M, Edemobi P, Vesely M, Cohen J. Association of Lichen Planus with Asthma and Allergic Rhinitis in the All of Us Research Program: A Cross-Sectional Study. Clinical And Experimental Dermatology 2024, llae101. PMID: 38589773, DOI: 10.1093/ced/llae101.
- Cognitive Bias in the Patient Encounter: Part II. Debiasing using an adaptive toolboxKo C, Gehlhausen J, Cohen J, Jiang Y, Myung P, Croskerry P. Cognitive Bias in the Patient Encounter: Part II. Debiasing using an adaptive toolbox. Journal Of The American Academy Of Dermatology 2024 PMID: 38588820, DOI: 10.1016/j.jaad.2024.02.061.
- Cognitive Bias in the Patient Encounter: Part I. Background and significanceKo C, Gehlhausen J, Cohen J, Croskerry P. Cognitive Bias in the Patient Encounter: Part I. Background and significance. Journal Of The American Academy Of Dermatology 2024 PMID: 38588821, DOI: 10.1016/j.jaad.2024.01.091.
- Gene trajectory inference for single-cell data by optimal transport metricsQu R, Cheng X, Sefik E, Stanley III J, Landa B, Strino F, Platt S, Garritano J, Odell I, Coifman R, Flavell R, Myung P, Kluger Y. Gene trajectory inference for single-cell data by optimal transport metrics. Nature Biotechnology 2024, 1-11. PMID: 38580861, DOI: 10.1038/s41587-024-02186-3.
- Spiny Keratoderma: Clinical and Histopathological Findings in a Series of 3 CasesHanly A, Turner N, Ko C, Panse G. Spiny Keratoderma: Clinical and Histopathological Findings in a Series of 3 Cases. American Journal Of Dermatopathology 2024, 46: 439-442. PMID: 38574081, DOI: 10.1097/dad.0000000000002705.
- A Patient With Oral Discomfort and Reduced Oral ApertureChen G, Roy S, Cohen J. A Patient With Oral Discomfort and Reduced Oral Aperture. JAMA 2024, 331: 1147-1148. PMID: 38436993, DOI: 10.1001/jama.2023.25945.
- Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cellsBangert C, Alkon N, Chennareddy S, Arnoldner T, Levine J, Pilz M, Medjimorec M, Ruggiero J, Cohenour E, Jonak C, Damsky W, Griss J, Brunner P. Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells. Nature Communications 2024, 15: 2839. PMID: 38565563, PMCID: PMC10987549, DOI: 10.1038/s41467-024-46540-0.
- TGF-β1 Drives Integrin-Dependent Pericyte Migration and Microvascular Destabilization in Fibrotic DiseasePellowe A, Wu M, Kang T, Chung T, Ledesma-Mendoza A, Herzog E, Levchenko A, Odell I, Varga J, Gonzalez A. TGF-β1 Drives Integrin-Dependent Pericyte Migration and Microvascular Destabilization in Fibrotic Disease. American Journal Of Pathology 2024, 194: 1171-1184. PMID: 38548268, DOI: 10.1016/j.ajpath.2024.02.021.
- Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)Silverberg J, Gooderham M, Paller A, Deleuran M, Bunick C, Gold L, Hijnen D, Calimlim B, Lee W, Teixeira H, Hu X, Zhang S, Yang Y, Grada A, Platt A, Thaçi D. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2). American Journal Of Clinical Dermatology 2024, 25: 485-496. PMID: 38528257, PMCID: PMC11070400, DOI: 10.1007/s40257-024-00853-4.
- Abstract 1167: Prospective analysis of pretreatment circulating CD4 memory T cell features associated with severe immunotherapy toxicityUsmani A, Earland N, Zhang W, Harris P, Bacchiocchi A, Sachs C, Nene A, Chen D, Sznol M, Halaban R, Newman A, Chaudhuri A. Abstract 1167: Prospective analysis of pretreatment circulating CD4 memory T cell features associated with severe immunotherapy toxicity. Cancer Research 2024, 84: 1167-1167. DOI: 10.1158/1538-7445.am2024-1167.
- Abstract 4745: A novel combination therapy targeting RAF, MEK and FAK to overcome skin cutaneous melanoma treatment resistanceLubrano S, Faraji F, Cervantes-Villagrana R, Ramirez S, Arang N, Officer A, Rigiracciolo D, Quiroz P, Bacchiocchi A, Halaban R, Coma S, Holmen S, Martini C, Pachter J, Aplin A, Gutkind J. Abstract 4745: A novel combination therapy targeting RAF, MEK and FAK to overcome skin cutaneous melanoma treatment resistance. Cancer Research 2024, 84: 4745-4745. DOI: 10.1158/1538-7445.am2024-4745.
- Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanomaSu D, Schoenfeld D, Ibrahim W, Cabrejo R, Djureinovic D, Baumann R, Rimm D, Khan S, Halaban R, Kluger H, Olino K, Galan A, Clune J. Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma. Journal For ImmunoTherapy Of Cancer 2024, 12: e008646. PMID: 38519058, PMCID: PMC10961546, DOI: 10.1136/jitc-2023-008646.
- Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia AreataPiliang M, Soung J, King B, Shapiro J, Rudnicka L, Farrant P, Magnolo N, Piraccini B, Luo X, Woodworth D, Schaefer G, Lejeune A, Wolk R. Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata. SKIN The Journal Of Cutaneous Medicine 2024, 8: s394. DOI: 10.25251/skin.8.supp.394.
- Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic DiseaseArmillei M, Lomakin I, Del Rosso J, Grada A, Bunick C. Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease. Antibiotics 2024, 13: 270. PMID: 38534705, PMCID: PMC10967556, DOI: 10.3390/antibiotics13030270.
- Rethinking Hidradenitis Suppurativa Management: Insights into Bacterial Interactions and Treatment EvolutionHuynh F, Damiani G, Bunick C. Rethinking Hidradenitis Suppurativa Management: Insights into Bacterial Interactions and Treatment Evolution. Antibiotics 2024, 13: 268. PMID: 38534703, PMCID: PMC10967558, DOI: 10.3390/antibiotics13030268.
- Immune Checkpoint Inhibitor-Induced Psoriasis Diagnosis, Management, and a Review of CasesPach J, Mbonu N, Bhullar S, Cohen J, Leventhal J. Immune Checkpoint Inhibitor-Induced Psoriasis Diagnosis, Management, and a Review of Cases. Dermatologic Clinics 2024, 42: 481-493. PMID: 38796277, DOI: 10.1016/j.det.2024.02.012.
- Benzoyl Peroxide Drug Products Form BenzeneKucera K, Zenzola N, Hudspeth A, Dubnicka M, Hinz W, Bunick C, Dabestani A, Light D. Benzoyl Peroxide Drug Products Form Benzene. Environmental Health Perspectives 2024, 132: 037702. PMID: 38483533, PMCID: PMC10939128, DOI: 10.1289/ehp13984.
- Association between atopic dermatitis and eating disorders: a cross-sectional study in the All of Us Research ProgramChen G, Xu S, White M, Cohen J. Association between atopic dermatitis and eating disorders: a cross-sectional study in the All of Us Research Program. British Journal Of Dermatology 2024, 190: 925-927. PMID: 38466772, DOI: 10.1093/bjd/ljae103.
- Cosmetic Directors on ACGME Program Requirements: A Cross-Sectional SurveyMinkis K, Stratman E, Shi V, Greywal T, Hu J, Suozzi K, Saikaly S, Ortiz A, Kang B, Alam M, members of the AACD Regulatory E, Kourosh A, Boucher A, Suggs A, Bar A, Cahn B, Robinson C, Schlick C, Hooper D, Antonovich D, Bolotin D, Hoss E, Ghareeb E, Hisham F, Alvarez G, Kuhn H, Luke J, Roberts J, Joo J, Orringer J, Labadie J, Shah K, Ward K, Kelly K, Shahabi L, Kole L, Tolaymat L, Dave L, Council M, Chow M, Yi M, Pearlstein M, Eshaq M, Deng M, Lawrence N, Vashi N, Kibbi N, Schenck O, Elsanadi R, Farah R, Wyles S, Yoo S, Nadir U, Petronic-Rosic V, Levin Y, Nawas Z. Cosmetic Directors on ACGME Program Requirements: A Cross-Sectional Survey. Journal Of The American Academy Of Dermatology 2024 PMID: 38460788, DOI: 10.1016/j.jaad.2024.01.085.
- Using Shame as a Signal to Talk about SuicideSiegel J, Ko C. Using Shame as a Signal to Talk about Suicide. Clinical Chemistry 2024, 70: 786-788. PMID: 38441566, DOI: 10.1093/clinchem/hvae017.
- How Efforts to Understand Somatic Mosaicism Will Impact DermatologyMortlock R, Choate K. How Efforts to Understand Somatic Mosaicism Will Impact Dermatology. Journal Of Investigative Dermatology 2024, 144: 453-455. PMID: 38395493, PMCID: PMC11009867, DOI: 10.1016/j.jid.2023.10.007.
- Syringotropic mycosis fungoides with clinical and histologic features of necrobiosis lipodica diabeticorumTorres-Piwinski M, Carlson K, Panse G, Girardi M. Syringotropic mycosis fungoides with clinical and histologic features of necrobiosis lipodica diabeticorum. JAAD Case Reports 2024 DOI: 10.1016/j.jdcr.2024.02.029.
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2Senna M, Mostaghimi A, Ohyama M, Sinclair R, Dutronc Y, Wu W, Yu G, Chiasserini C, Somani N, Holzwarth K, King B. Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2. Journal Of The European Academy Of Dermatology And Venereology 2024, 38: 583-593. PMID: 38391212, DOI: 10.1111/jdv.19665.
- Cutaneous diatoms from diatomaceous earth mimicking myiasis infectionRoy S, Micevic G, McNiff J, Christensen S, Cowper S. Cutaneous diatoms from diatomaceous earth mimicking myiasis infection. Pathology 2024 PMID: 38471986, DOI: 10.1016/j.pathol.2023.12.416.
- The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the LiteratureBelzer A, Pach J, Valido K, Leventhal J. The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature. American Journal Of Clinical Dermatology 2024, 25: 435-445. PMID: 38366030, DOI: 10.1007/s40257-024-00847-2.
- Isolated single or pauci-nail lichen planus, three casesJiang R, Kim R, Christensen S, Zubek A. Isolated single or pauci-nail lichen planus, three cases. JAAD Case Reports 2024, 46: 52-56. PMID: 38510835, PMCID: PMC10951446, DOI: 10.1016/j.jdcr.2024.01.031.
- 533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposureBunick C, Chovatiya R, Guttman E, Shahriari M, Boguniewicz M, Gao X, Greiwe J, Blauvelt A, Schuttelaar M, Irvine A, Levy G, Platt A, Dilley D, Teixeira H, Altman K, Grada A, Silverberg J. 533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure. British Journal Of Dermatology 2024, 190: ii35-ii36. DOI: 10.1093/bjd/ljad498.037.
- 504 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitisBunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. 504 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis. British Journal Of Dermatology 2024, 190: ii9-ii10. DOI: 10.1093/bjd/ljad498.012.
- A pilot study of p53 immunohistochemistry in atypical squamous lesions, using a vulvar scoring systemNiu N, Roy S, Ko C. A pilot study of p53 immunohistochemistry in atypical squamous lesions, using a vulvar scoring system. Journal Of Cutaneous Pathology 2024, 51: 379-386. PMID: 38317537, DOI: 10.1111/cup.14591.
- Rapidly progressive subungual gray-brown melanonychiaEcheandia-Francis C, Nock M, Myung P, Zubek A. Rapidly progressive subungual gray-brown melanonychia. JAAD Case Reports 2024, 44: 113-115. PMID: 38414828, PMCID: PMC10897537, DOI: 10.1016/j.jdcr.2024.01.013.
- Topical trametinib for epidermal and sebaceous nevi in a child with Schimmelpenning‐Feuerstein‐Mims syndromeHaller C, Leszczynska M, Brichta L, Maier E, Riddington I, Choate K, Levy M. Topical trametinib for epidermal and sebaceous nevi in a child with Schimmelpenning‐Feuerstein‐Mims syndrome. Pediatric Dermatology 2024, 41: 523-525. PMID: 38273779, PMCID: PMC11096062, DOI: 10.1111/pde.15523.
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramKing B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, Sinclair R, Mesinkovska N, Paul C, Gong Y, Anway S, Tran H, Wolk R, Zwillich S, Lejeune A. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. American Journal Of Clinical Dermatology 2024, 25: 299-314. PMID: 38263353, PMCID: PMC10867086, DOI: 10.1007/s40257-024-00846-3.
- Structural Basis for p19 Targeting by Anti–IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in PsoriasisDaniele S, Eldirany S, Damiani G, Ho M, Bunick C. Structural Basis for p19 Targeting by Anti–IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in Psoriasis. JID Innovations 2024, 4: 100261. PMID: 38445231, PMCID: PMC10914523, DOI: 10.1016/j.xjidi.2024.100261.
- Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed CombinationsGhannoum M, Gamal A, Kadry A, Del Rosso J, Bunick C, Stein Gold L, Kircik L, Harper J. Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations. SKIN The Journal Of Cutaneous Medicine 2024, 8: s355. DOI: 10.25251/skin.8.supp.355.
- Triple-Combination Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Moderate-to-Severe Acne: Efficacy and Safety Results From a Pooled Phase 3 AnalysisStein Gold L, Gold M, Kircik L, Harper J, Del Rosso J, Bunick C, Bhatia N, Baldwin H, Draelos Z, Callender V, Lain E. Triple-Combination Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Moderate-to-Severe Acne: Efficacy and Safety Results From a Pooled Phase 3 Analysis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s357. DOI: 10.25251/skin.8.supp.357.
- In‐person validation of the Ichthyosis Scoring SystemEcheandia‐Francis C, Sun Q, Asch S, Bayart C, Benjamin L, Cipriano S, Craiglow B, Dyer J, Levy M, Lilly E, Newell B, Liang J, Gan G, Deng Y, Paller A, Choate K. In‐person validation of the Ichthyosis Scoring System. Pediatric Dermatology 2024, 41: 247-252. PMID: 38234066, DOI: 10.1111/pde.15508.
- Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed CombinationsGhannoum M, Gamal A, Kadry A, Del Rosso J, Bunick C, Stein Gold L, Kircik L, Harper J. Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations. SKIN The Journal Of Cutaneous Medicine 2024, 8: s354. DOI: 10.25251/skin.8.supp.354.
- Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic DermatitisBunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Stein Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s309. DOI: 10.25251/skin.8.supp.309.
- Triple-Combination Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Moderate-to-Severe Acne: Efficacy and Safety Results From a Pooled Phase 3 AnalysisStein Gold L, Gold M, Kircik L, Harper J, Del Rosso J, Bunick C, Bhatia N, Baldwin H, Draelos Z, Callender V, Lain E. Triple-Combination Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Moderate-to-Severe Acne: Efficacy and Safety Results From a Pooled Phase 3 Analysis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s339. DOI: 10.25251/skin.8.supp.339.
- Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancyRen J, Liao X, Lewis J, Chang J, Qu R, Carlson K, Foss F, Girardi M. Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy. Nature Communications 2024, 15: 519. PMID: 38225288, PMCID: PMC10789731, DOI: 10.1038/s41467-024-44786-2.
- Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitorsBang A, Fay C, LeBoeuf N, Etaee F, Leventhal J, Sibaud V, Arbesman J, Wang J, Kwong B. Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors. Breast Cancer Research And Treatment 2024, 204: 643-647. PMID: 38224427, DOI: 10.1007/s10549-023-07217-2.
- Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trialMesinkovska N, King B, Vañó‐Galván S, Shimomura Y, Jedynak J, McCollam J, Pierce E, Ellinwood A, Sinclair R. Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial. JEADV Clinical Practice 2024, 3: 528-535. DOI: 10.1002/jvc2.327.
- Psoriasis associated with inflammatory bowel disease: a cross‐sectional analysis in the NIH All of Us Research ProgramJoel M, Wride A, Cohen J. Psoriasis associated with inflammatory bowel disease: a cross‐sectional analysis in the NIH All of Us Research Program. International Journal Of Dermatology 2024, 63: e82-e83. PMID: 38204174, PMCID: PMC10922412, DOI: 10.1111/ijd.17015.
- Interferon-stimulated neutrophils as a predictor of immunotherapy responseBenguigui M, Cooper T, Kalkar P, Schif-Zuck S, Halaban R, Bacchiocchi A, Kamer I, Deo A, Manobla B, Menachem R, Haj-Shomaly J, Vorontsova A, Raviv Z, Buxbaum C, Christopoulos P, Bar J, Lotem M, Sznol M, Ariel A, Shen-Orr S, Shaked Y. Interferon-stimulated neutrophils as a predictor of immunotherapy response. Cancer Cell 2024, 42: 253-265.e12. PMID: 38181798, PMCID: PMC10864002, DOI: 10.1016/j.ccell.2023.12.005.
- Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature ReviewTurner N, Ko C, McNiff J, Galan A. Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature Review. American Journal Of Dermatopathology 2024, 46: 21-30. PMID: 37982498, DOI: 10.1097/dad.0000000000002584.
2023
- Characterizing skin and soft tissue infections in patients with cancer on systemic oncologic therapy: A single institution retrospective analysis from the outpatient and inpatient oncodermatology servicePach J, Nelson C, Leventhal J. Characterizing skin and soft tissue infections in patients with cancer on systemic oncologic therapy: A single institution retrospective analysis from the outpatient and inpatient oncodermatology service. JAAD International 2023, 15: 21-23. PMID: 38371669, PMCID: PMC10869938, DOI: 10.1016/j.jdin.2023.11.011.
- Granuloma annulare is associated with an increased risk of hematologic malignancies: A multicenter cohort study using TriNetXGarate D, Thang C, Damsky W, Rosenbach M, Golovko G, Wilkerson M, Barbieri J. Granuloma annulare is associated with an increased risk of hematologic malignancies: A multicenter cohort study using TriNetX. Journal Of The American Academy Of Dermatology 2023, 90: 862-864. PMID: 38147901, DOI: 10.1016/j.jaad.2023.12.028.
- Retrospective assessment of immunologic and histologic heterogeneity in granuloma annulare by cytokine stainingHwang E, Lee T, Okifo K, Murphy M, Damsky W. Retrospective assessment of immunologic and histologic heterogeneity in granuloma annulare by cytokine staining. International Journal Of Dermatology 2023, 63: 655-659. PMID: 38135676, PMCID: PMC11055676, DOI: 10.1111/ijd.16998.
- Depression in patients with Raynaud’s phenomenon: A case-control study in the National Institutes of Health's A ll of Us Research ProgramChen G, Shaw K, Xu S, Hashemi K, Castillo R, Vleugels R, Cohen J. Depression in patients with Raynaud’s phenomenon: A case-control study in the National Institutes of Health's A ll of Us Research Program. Journal Of The American Academy Of Dermatology 2023, 90: 857-859. PMID: 38128831, DOI: 10.1016/j.jaad.2023.12.015.
- Polyinosinic: polycytidylic acid induced inflammation enhances while lipopolysaccharide diminishes alloimmunity to platelet transfusion in miceTran J, Muench M, Gaillard B, Darst O, Tomayko M, Jackman R. Polyinosinic: polycytidylic acid induced inflammation enhances while lipopolysaccharide diminishes alloimmunity to platelet transfusion in mice. Frontiers In Immunology 2023, 14: 1281130. PMID: 38146372, PMCID: PMC10749330, DOI: 10.3389/fimmu.2023.1281130.
- Obsessive–compulsive disorder among patients with atopic dermatitis: a case–control study in the All of Us research programChen G, Fan R, Leasure A, Levey D, Damsky W, Cohen J. Obsessive–compulsive disorder among patients with atopic dermatitis: a case–control study in the All of Us research program. Archives Of Dermatological Research 2023, 316: 11. PMID: 38038754, DOI: 10.1007/s00403-023-02767-3.
- Le tralokinumab module le profil transcriptomique de la peau (lésionnelle ou non) chez les adolescents atteints de dermatite atopique modérée à sévèreQuiles-Tsimaratos N, da Rosa J, Simpson E, Soong W, Antaya R, Imafuku S, Pilger S, Litman T, Røpke M, Arlert P, Guttman-Yassky E. Le tralokinumab module le profil transcriptomique de la peau (lésionnelle ou non) chez les adolescents atteints de dermatite atopique modérée à sévère. Annales De Dermatologie Et De Vénéréologie - FMC 2023, 3: a61. DOI: 10.1016/j.fander.2023.09.042.
- Analyse de la tolérance du baricitinib chez les patients adultes atteints de pelade sévère issus de 2 essais cliniques randomisés sur une période d’exposition médiane de 1,6 années et maximale de 3,6 annéesKing B, Ko J, Piraccini B, Shimomura Y, Dutronc Y, Wu W, Yang F, Holzwarth K, Chiasserini C, Sinclair R, Leveque C. Analyse de la tolérance du baricitinib chez les patients adultes atteints de pelade sévère issus de 2 essais cliniques randomisés sur une période d’exposition médiane de 1,6 années et maximale de 3,6 années. Annales De Dermatologie Et De Vénéréologie - FMC 2023, 3: a348-a349. DOI: 10.1016/j.fander.2023.09.595.
- Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2Senna M, Mostaghimi A, Ohyama M, Sinclair R, Dutronc Y, Wu W, Guanglei Y, Chiasserini C, Somani N, King B, Leveque C. Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2. Annales De Dermatologie Et De Vénéréologie - FMC 2023, 3: a336-a337. DOI: 10.1016/j.fander.2023.09.580.
- Analyse intégrée de la tolérance de ritlécitinib dans le traitement de la pelade, données issues des phases 2 et phases 3 du programme de développement clinique ALLEGROKing B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, Rodney S, Anway S, Wajsbrot D, Lejeune A, Zwillich S. Analyse intégrée de la tolérance de ritlécitinib dans le traitement de la pelade, données issues des phases 2 et phases 3 du programme de développement clinique ALLEGRO. Annales De Dermatologie Et De Vénéréologie - FMC 2023, 3: a364-a365. DOI: 10.1016/j.fander.2023.09.614.
- Enhanced alloresponse to platelet transfusion due to immune dysregulation following ablative chemotherapy in miceJackman R, Darst O, Gaillard B, Tran J, Tomayko M, Muench M. Enhanced alloresponse to platelet transfusion due to immune dysregulation following ablative chemotherapy in mice. Frontiers In Immunology 2023, 14: 1281123. PMID: 38090570, PMCID: PMC10711281, DOI: 10.3389/fimmu.2023.1281123.
- Obstructive sleep apnea among patients with psoriasis: A case-control study in the All of Us Research ProgramShaw V, Tobias L, Cohen J. Obstructive sleep apnea among patients with psoriasis: A case-control study in the All of Us Research Program. Journal Of The American Academy Of Dermatology 2023, 90: 666-668. PMID: 38008412, DOI: 10.1016/j.jaad.2023.11.031.
- Association between atopic dermatitis and hypertension and hyperlipidemia: A cross-sectional study in the All of Us Research ProgramCraver A, Chen G, Cohen J. Association between atopic dermatitis and hypertension and hyperlipidemia: A cross-sectional study in the All of Us Research Program. Journal Of The American Academy Of Dermatology 2023, 90: 819-821. PMID: 38008413, DOI: 10.1016/j.jaad.2023.11.026.
- Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia AreataSenna M, Kwon O, Piraccini B, Sinclair R, Ball S, Ding Y, Chen Y, Dutronc Y, King B. Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata. Dermatology And Therapy 2023, 13: 3209-3220. PMID: 37991697, PMCID: PMC10689319, DOI: 10.1007/s13555-023-01063-2.
- Association between atopic dermatitis and inflammatory bowel disease among US adults in the All of Us Research ProgramJoel M, Damsky W, Cohen J, Wride M. Association between atopic dermatitis and inflammatory bowel disease among US adults in the All of Us Research Program. Clinical And Experimental Dermatology 2023, 49: 390-392. PMID: 37967342, PMCID: PMC10957220, DOI: 10.1093/ced/llad397.
- A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily betterDjureinovic D, Weiss S, Krykbaeva I, Qu R, Vathiotis I, Moutafi M, Zhang L, Perdigoto A, Wei W, Anderson G, Damsky W, Hurwitz M, Johnson B, Schoenfeld D, Mahajan A, Hsu F, Miller-Jensen K, Kluger Y, Sznol M, Kaech S, Bosenberg M, Jilaveanu L, Kluger H. A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better. Molecular Cancer 2023, 22: 182. PMID: 37964379, PMCID: PMC10644655, DOI: 10.1186/s12943-023-01884-x.
- Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 StudyPiliang M, Lynde C, King B, Mirmirani P, Sinclair R, Wolk R, Zwillich S, Tran H, Zhang F, Takiya L. Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study. SKIN The Journal Of Cutaneous Medicine 2023, 7: s293. DOI: 10.25251/skin.7.supp.293.
- Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2King B, Ohyama M, Senna M, Shapiro J, Dutronc Y, Kolodsick J, Yu G, Liu C, Chiasserini C, Piraccini B. Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2. SKIN The Journal Of Cutaneous Medicine 2023, 7: s296. DOI: 10.25251/skin.7.supp.296.
- Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic DermatitisBunick C, Bhatia N, Del Rosso J, Draelos Z, Eichnfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Stein Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis. SKIN The Journal Of Cutaneous Medicine 2023, 7: s251. DOI: 10.25251/skin.7.supp.251.
- Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial ProgramKing B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, Sinclair R, Anway S, Wajsbrot D, Lejeune A, Zwillich S. Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program. SKIN The Journal Of Cutaneous Medicine 2023, 7: s291. DOI: 10.25251/skin.7.supp.291.
- Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT StudiesSoung J, King B, Tziotzios C, Rudnicka L, Joly P, Gooderham M, Sinclair R, Wajsbrot D, Tran H, Wolk R. Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies. SKIN The Journal Of Cutaneous Medicine 2023, 7: s294. DOI: 10.25251/skin.7.supp.294.
- Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authorsShipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors. British Journal Of Dermatology 2023, 190: 138-138. PMID: 37947404, DOI: 10.1093/bjd/ljad342.
- Inhibition of T-cell activity in alopecia areata: recent developments and new directionsPasseron T, King B, Seneschal J, Steinhoff M, Jabbari A, Ohyama M, Tobin D, Randhawa S, Winkler A, Telliez J, Martin D, Lejeune A. Inhibition of T-cell activity in alopecia areata: recent developments and new directions. Frontiers In Immunology 2023, 14: 1243556. PMID: 38022501, PMCID: PMC10657858, DOI: 10.3389/fimmu.2023.1243556.
- 1025 Tumor-specific CD8+ T cells epigenetically licensed by IL-7R are critical for anti-tumor immunity in melanomaMicevic G, Daniels A, Flem-Karlsen K, Park K, Talty R, McGeary M, Mirza H, Blackburn H, Sefik E, Cheung J, Hornick N, Aizenbud L, Joshi N, Kluger H, Iwasaki A, Bosenberg M, Flavell R. 1025 Tumor-specific CD8+ T cells epigenetically licensed by IL-7R are critical for anti-tumor immunity in melanoma. 2023, a1133-a1133. DOI: 10.1136/jitc-2023-sitc2023.1025.
- Lipid Nanoparticle-Mediated Hit-and-Run Approaches Yield Efficient and Safe In Situ Gene Editing in Human SkinBolsoni J, Liu D, Mohabatpour F, Ebner R, Sadhnani G, Tafech B, Leung J, Shanta S, An K, Morin T, Chen Y, Arguello A, Choate K, Jan E, Ross C, Brambilla D, Witzigmann D, Kulkarni J, Cullis P, Hedtrich S. Lipid Nanoparticle-Mediated Hit-and-Run Approaches Yield Efficient and Safe In Situ Gene Editing in Human Skin. ACS Nano 2023, 17: 22046-22059. PMID: 37918441, PMCID: PMC10655174, DOI: 10.1021/acsnano.3c08644.
- 1437 Proteomic profiling of tumor microenvironment in desmoplastic melanoma using the nanostring geomx digital spatial profilerSu D, Schoenfeld D, Ibrahim W, Baumann R, Rimm D, Kluger H, Olino K, Galan A, Clune J. 1437 Proteomic profiling of tumor microenvironment in desmoplastic melanoma using the nanostring geomx digital spatial profiler. 2023, a1600-a1600. DOI: 10.1136/jitc-2023-sitc2023.1437.